The burden of tuberculosis among patients with non-small cell lung carcinoma in a tertiary care center

被引:0
|
作者
Mahishi, Niranjan [1 ]
Bala, Kiran [2 ]
Malik, Prabhat [3 ]
Ranjan, Piyush [4 ]
Kumar, Arvind [4 ]
Soneja, Manish [4 ]
Mohan, Anant [5 ]
Singh, Urvashi B. [2 ]
机构
[1] All India Inst Med Sci, Dept Med & Microbiol, New Delhi, India
[2] All India Inst Med Sci, Dept Microbiol, New Delhi, India
[3] All India Inst Med Sci, Dept Med Oncol, New Delhi, India
[4] All India Inst Med Sci, Dept Gen Med, New Delhi, India
[5] All India Inst Med Sci, Dept Pulm Crit Care & Sleep Disorder, New Delhi, India
关键词
Pulmonary tuberculosis; Lung cancer; Adenocarcinoma; Mycobacterium tuberculosis; PULMONARY TUBERCULOSIS; CANCER; RISK;
D O I
10.1016/j.ijmmb.2024.100729
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background Lung cancer and tuberculosis share similar risk factors, clinical spectrum, radiological features and it is difficult to differentiate but it is important to diagnose both conditions for targeted therapy and better outcome. Aims Our primary objective was to estimate the proportion of TB in primary biopsy proven non-small cell lung carcinoma (NSCLC) cases. Material & methods This prospective observational study was conducted in the Departments of Medicine/Pulmonary Medicine/Medical Oncology and Microbiology at the All India Institute of Medical Sciences, New Delhi for a period of 2 years (January 2020-December 2021). Patients with biopsy proven, primary non-small cell lung cancer were recruited and sputum samples were subjected to microbiological investigations to confirm tuberculosis. Comparison was done in two groups of lung cancer patients with confirmed TB (Group A) and without confirmed tuberculosis (Group B). Results Total 75 patients with biopsy proven, primary NSCLC were recruited and 16 % (12/75) were diagnosed with confirmed TB. Adenocarcinoma (36.48 %) and Squamous cell carcinoma (33.44 %) were the two predominant histopathological subtypes of NSCLC. About 57 (76 %) of them were found to be in stage IV of Lung cancer at initial presentation itself (75 % in group A & 74.6 % in group B; p value < 0.80). A majority of patients (11/12 cases; 91 %) of group A were males with a mean age of 59 +/- 7.5 years. The upper lobes of the lung were involved in 65 % (49/75) of the cases and showing a mass lesion on imaging (75 % in group A & 65 % in group B; p value < 0.52). Kaplan Meier survival revealed a median survival time of 11 months in subjects with only NSCLC and a median survival time of 4 months in the group with concomitant TB and NSCLC (p value < 0.44).
引用
收藏
页数:6
相关论文
共 50 条
  • [41] KRAS Amplification in Non-Small Cell Lung Carcinoma
    Stiedl, A. C.
    Wagner, P. L.
    Wilbertz, T.
    Altorki, N. K.
    Perner, S. R.
    MODERN PATHOLOGY, 2010, 23 : 414A - 414A
  • [42] NON-SMALL CELL-CARCINOMA OF THE LUNG - INTRODUCTION
    GOLOMB, HM
    SEMINARS IN ONCOLOGY, 1983, 10 (01) : 1 - 2
  • [43] A Case of Hypertrophic Pulmonary Osteoarthropathy in Coexistent Non-small Cell Lung Carcinoma and Pulmonary Tuberculosis
    Midhun, J.
    Jacob, Reuben
    INDIAN JOURNAL OF RESPIRATORY CARE, 2024, 13 (03) : 197 - 199
  • [44] Subtyping of Non-Small Cell Lung Carcinomas in Bronchoscopic Biopsies: A Tertiary Care Centre Experience
    Vaidya, Mihir Mohan
    Rane, Sharada R.
    Puranik, Shaila C.
    JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH, 2018, 12 (11) : EC1 - EC4
  • [45] THE SIGNIFICANCE OF NEUROENDOCRINE DIFFERENTIATION IN PATIENTS WITH RESECTED NON-SMALL CELL LUNG CARCINOMA
    Percinel, Sibel
    Bircan, Sema
    Sertcelik, Ayse
    Kayi, Ayten Cangir
    GAZI MEDICAL JOURNAL, 2009, 20 (02): : 64 - 71
  • [46] Neoadjuvant Erlotinib Treatment in Patients with Resectable Non-Small Cell Lung Carcinoma
    Van Gool, Matthijs
    Kiomp, Houke
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S644 - S645
  • [47] Practical implementation of the IORT for patients with non-small cell lung carcinoma (NSCLC)
    Kapp, K. S.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2008, 184 : 189 - 190
  • [48] Prognostic value of DNA cytometry in patients with non-small cell lung carcinoma
    Skuballa, A
    Starke, U
    Achatzy, R
    Hutschenreiter, J
    6TH EUROPEAN CONFERENCE ON GENERAL THORACIC SURGERY, 1998, : 89 - 92
  • [49] Prognosis of non-small cell lung carcinoma in patients with previous gastric cancer
    Tsubokawa, Norifumi
    Mimae, Takahiro
    Aokage, Keiju
    Hattori, Aritoshi
    Suzuki, Kenji
    Nagal, Kenji
    Tsubol, Masahiro
    Okada, Morihito
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [50] Characterization of tumour mutation burden in patients with non-small cell lung cancer and interstitial lung disease
    Kobayashi, Haruki
    Serizawa, Masakuni
    Naito, Tateaki
    Konno, Hayato
    Kojima, Hideaki
    Mizuno, Tetsuya
    Isaka, Mitsuhiro
    Endo, Masahiro
    Nagashima, Takeshi
    Kusuhara, Masatoshi
    Urakami, Kenichi
    Ohshima, Keiichi
    Yamaguchi, Ken
    Ohde, Yasuhisa
    Takahashi, Toshiaki
    RESPIROLOGY, 2020, 25 (08) : 850 - 854